Table 2 Acceptability rating for toxicity profiles of possible genomically- directed postneoadjuvant treatment regimens with varying degrees of benefit
From: Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer
Toxicity profile | Absolute risk reduction | Mean score | Std Dev |
|---|---|---|---|
A (capecitabine) | 5 | 38.84 | 32.21 |
A (capecitabine) | 15 | 57.40 | 31.10 |
A (capecitabine) | 35 | 86.28 | 20.43 |
B (immunotherapy) | 5 | 32.89 | 30.00 |
B (immunotherapy) | 15 | 53.31 | 29.47 |
B (immunotherapy) | 35 | 82.0 | 22.54 |
C (parp inhibitor) | 5 | 43.22 | 34.45 |
C (parp inhibitor) | 15 | 62.12 | 30.53 |
C (parp inhibitor) | 35 | 87.71 | 21.56 |
D (PI3K inhibitor) | 5 | 30.80 | 29.46 |
D (PI3K inhibitor) | 15 | 51.28 | 31.09 |
D (P inhibitor) | 35 | 78.20 | 25.28 |
